Meiji Seika Kaisha, Ltd.

Meiji Seika Pharma Co., Ltd.

Japan As Represented by Director General of Agency of Industrial Science

Meiji Seika Kabushiki Kaisha

Meji Seika Kaisha Ltd.

Mitsui Chemicals Crop & Life Solutions, Inc.

Naomi Sumida

Manabu Watanabe

Koji Yanai

Takeshi Murakami

Takashi Yaguchi

Takayoshi Tamura

Naoki Mido

Tatsuki Moriya

Toshiaki Kono

Jinichiro Koga

Kaoru Aoyagi

Akitaka Nakane

Toru Hamaya

Kouichirou Murashima

Koichiro Murashima

Takayoshi Fukushima

Tomoko Nishimura

Koei Kobayashi

Shuichi Gomi

Kentaro Yamamoto

Takashi Yamanobe

Yuko Baba

Horst Kleinkauf

Naoki Midoh

Rainer Zocher

Hiroyuki Anzai

Fusuke Mazuka

Koichi Miyamoto

Masato Tani

Sato Aihara

Yuko Nakamura

Kouji Yanai

Yasumasa Ota

The genomic DNA of Streptoverticillium sp. 3-7, which produces UK-2, was analyzed to identify a region expected to be a UK-2 biosynthetic gene cluster. Moreover, by colony hybridization, DNAs in the region were successfully isolated. Further, the DNAs were used to prepare a strain in which the genes present in the region were disrupted. The strain was found not to produce UK-2. It was verified that the genomic region was the UK-2 biosynthetic gene cluster. Furthermore, Streptoverticillium sp. 3-7 was transformed by introduction of a vector in which the isolated UK-2 biosynthetic gene cluster was inserted. It was also found out that the UK-2 productivity by the transformant was improved about 10 to 60 times or more in comparison with that of the parental strain. Moreover, it was revealed that 2 copies of the UK-2 biosynthetic gene cluster were present per cell in these transformants, respectively.

UK-2 biosynthetic gene and method for improving UK-2 productivity using the same

The present invention relates to novel aminoglycoside antibiotics, a process for producing the same, and pharmaceutical use thereof. More specifically, the present invention relates to compounds represented by formula (I), a process for producing the same, and use of the same as antimicrobial agents. wherein R represents amino or hydroxyl.

Aminoglycoside antibiotics, process for producing the same, and pharmaceutical use thereof

The genomic DNA ofsp. 3-7, which produces UK-2, was analyzed to identify a region expected to be a UK-2 biosynthetic gene cluster. Moreover, by colony hybridization, DNAs in the region were successfully isolated. Further, the DNAs were used to prepare a strain in which the genes present in the region were disrupted. The strain was found not to produce UK-2. It was verified that the genomic region was the UK-2 biosynthetic gene cluster. Furthermore,sp. 3-7 was transformed by introduction of a vector in which the isolated UK-2 biosynthetic gene cluster was inserted. It was also found out that the UK-2 productivity by the transformant was improved about 10 to 60 times or more in comparison with that of the parental strain. Moreover, it was revealed that 2 copies of the UK-2 biosynthetic gene cluster were present per cell in these transformants, respectively.

There is provided a nucleic acid construct comprising a pyripyropene biosynthetic gene cluster and a marker gene. The nucleic acid construct according to the present invention provides an inexpensive and highly productive method for producing pyripyropene.

Nucleic acid construct comprising pyripyropene biosynthetic gene cluster and marker gene

Disclosed are a ketoreductase mutant which can be used for an efficient production of daunorubicin derivatives, a DNA encoding the mutant, a transformant prepared by introducing the DNA thereinto to produce a daunorubicin derivative, and a process of producing a daunorubicin derivative using the transformant. The ketoreductase mutant has an amino acid sequence in which one amino acid residue or two or more amino acid residues selected from the group consisting of amino acids located at positions corresponding to the 42nd, 149th, 153rd, 270th, and 306th amino acids in the amino acid sequence of a ketoreductase (EvaE) from a chlororemomycin-producing bacterium () are substituted with another amino acid residues.

Ketoreductase mutant

The present invention relates to a process for efficiently amplifying a giant DNA. More particularly, the present invention relates to a process for amplifying DNA in a cell, comprising amplifying the DNA as the target of amplification in the presence of DNAs selected from the following (i), (ii) and (iii):

Process for amplifying DNA in cells

Disclosed is a transformant prepared by introducing a ketoreductase gene involved in the biosynthesis of L-epivancosamine into an actinobacterium originally capable of producing daunorubicin. Also disclosed is a process of efficiently producing a non-natural daunorubicin derivative using the transformant. The transformant is capable of efficiently producing a non-natural daunorubicin derivative such as epidaunorubicin.

Transformant and method for production of non-natural antibiotic

The present invention provides a protein having saponin-decomposing activity, more specifically a protein which can decompose a glycoside having soyasapogenol B as an aglycone to produce soyasapogenol B, a polynucleotide encoding such a protein, and a method of producing soyasapogenol B on a large scale using the same. A protein according to the present invention are concerned with (a), (b) or (c), namely (a) a protein comprising an amino acid sequence selected from the group consisting of the amino acid sequences shown in SEQ ID NOs: 2, 4, and 6; (b) a protein that has at least 50% homology to the protein comprising the amino acid sequence of the sequence described in (a) and having saponin-decomposing activity; or (c) a protein comprising a modified amino acid sequence of the sequence described in (a) that has one or more amino acid residues deleted, substituted, inserted, or added and having saponin-decomposing activity.

Saponin-decomposing enzyme, gene thereof and large-scale production system for producing soyasapogenol B

Saponin-decomposing enzyme, gene thereof and large-scale production sytem for producing soyasapogenol B

An objective of the present invention is to provide a method for producing substance PF1022 derivatives, in particular PF1022-220 and PF1022-260, by a direct fermentation method, and a transformant to be used for this method. According to the present invention, there is provided a transformant producing substance FF1022 derivatives, which can be obtained by introducing a genes involved in a biosynthetic pathway from chorismic acid to p-aminophenylpyruvic acid, including a papA gene encoding 4-amino-4-deoxychorismate synthase. which gene comprises the DNA sequence encoding the amino acid sequence of SEQ ID NO: 2; a papB gene encoding 4-amino-4-deoxyclaismate mutase, which gene comprises the DNA sequence encoding the amino acid sequence of SEQ ID NO: 4; and a papC gene encoding 4-amino-4-deoxyprepbenate dehydrogenase, which gene comprises the DNA sequence encoding the amino acid sequence of SEQ ID NO: 6, into a phenylalanine auxotrophic host induced from an organism that produces a substance PF1022. According to the present invention, there is also provided a process of producing substance PF1022 derivative, comprising steps of culturing the above-mentioned transformant and collecting the substance PF1022 derivatives.

Transformants producing substance pf1022 derivatives, methods for producing the same, and novel biosynthesis genes

There is provided an endoglucanase enzyme, which is useful for reducing fuzz of regenerated cellulose-containing fabrics, improving the touch and appearance, color clarification, localized variation in color, reducing stiffness and using it as components of a detergent, as well as deinking waste paper and improving freeness of paper pulp. A cDNA coding for the endoglucanase enzyme NCE5 was cloned and its DNA sequence and amino acid sequence derived from it were determined.

Endoglucanase enzyme NCE5 and cellulase preparations containing the same

Saponin-digesting enzymes, genes thereof and soyasapogenol B mass production system

Growing community of inventors

Odawara, Japan

Naomi Sumida